React4life Updates

React4Life publishes a new study showcasing a dynamic 3D ovarian cancer model within the MIVO® platform. By mimicking systemic drug perfusion, the model accurately predicts in vivo responses in just one week—accelerating efficacy testing and reducing animal use in cancer drug development

We are proud to participate at SLAS 2022.
SLAS2022 is the main event of SLAS (Society for Laboratory Automation and Screening), which will connect thousands of scientists, researchers, academics, and professionals. It is the right place to learn about new technologies and automation that will lead the transformation of life sciences research.

Silvia Scaglione won the Women Startup Award while competing in the final of the 13th GammaDonna Award. From the world’s oldest pasta factory to cutting‑edge biotech, the GammaDonna event celebrates Italian female entrepreneurship and aims to shrink the gender gap.

MIVO® represents a major advancement in organ-on-chip technology, overcoming the limitations of traditional 2D cultures and miniature microfluidic systems. Designed to support clinically relevant 3D tissues and multi-organ configurations under controlled fluid dynamics, MIVO® enables more predictive drug testing and accelerates the translation of in vitro findings into effective therapies.

Silvia Scaglione, Chief Scientist at React4life, recognized in Pasqua Vini’s “Innovation is never conventional” project for her leadership in organ-on-chip development and translational biomedical research.

Urban pollution is one of the most pressing challenges for skin health. MIVO® provides a scientifically advanced, physiologically relevant method to evaluate true anti-pollution efficacy, measuring pollutant penetration through realistic skin models and delivering reliable, quantifiable data that supports innovation and credible skincare claims.

React4Life publishes a new study showcasing a dynamic 3D ovarian cancer model within the MIVO® platform. By mimicking systemic drug perfusion, the model accurately predicts in vivo responses in just one week—accelerating efficacy testing and reducing animal use in cancer drug development.

A collaborative effort between React4life and MatTek, this work advances intestinal permeability research using the MIVO® fluidic platform and EpiIntestinal™ tissues. The partnership delivers a human-relevant, dynamic model to study healthy, impaired, and recovering gut barriers with unprecedented physiological fidelity.

MIVO® Organ-on-Chip technology elevates personalized cancer therapy by integrating patient-derived organoids and tissue slices into a dynamic, physiologically accurate microenvironment—unlocking more predictive, patient-specific treatment strategies.

Cardio-Cov, a research project funded by Regione Lombardia and led by Centro Cardiologico Monzino in collaboration with INMI Lazzaro Spallanzani and React4Life, investigates how SARS-CoV-2 affects the heart. Using React4Life’s MIVO® organ-on-chip technology, the project models cardiac inflammation and fibrosis to identify new cardioprotective therapies against COVID-19.